Related Experiment Videos
Cryptococcal meningitis in patients with AIDS
1Department of Medicine, University of Alabama School of Medicine, Birmingham.
Abstract:
The Cryptococcus has become a major cause of meningitis in patients infected with the human immunodeficiency virus (HIV), and the expression of cryptococcal infection in this population of patients is quite unique. Often the infection is devoid of inflammatory response and is associated with very high antigen and fungal titers. Response to amphotericin therapy is erratic, and relapse is common. We have asked Dr. William E. Dismukes, principal investigator of the NIAID Mycoses Study Group, to discuss the following clinical questions: When and how does cryptococcal infection in HIV-infected patients present? How does it differ in HIV-infected and non-HIV-infected individuals? How is the diagnosis established? What is the sensitivity of the CSF cryptococcal antigen test? Is the serum antigen test of any value? What is the best way to treat patients--the recommended drugs, dosages, and duration of therapy? Is maintenance therapy necessary, and finally, what drugs are available for it? [Please note that an AIDS training program is now available for members of the Infectious Diseases Society of America and that details of this program appear in the Notices section of this Journal issue (pages 859-60).]
Insights
Cryptococcus meningitis in human immunodeficiency virus (HIV)-infected patients presents uniquely with low inflammation and high fungal loads. Treatment response is variable, with frequent relapses, necessitating specific therapeutic strategies.
Area of Science:
- Infectious Diseases
- Mycology
- Immunology
Background:
- Cryptococcus is a leading cause of meningitis in HIV patients.
- Infections in this population exhibit unique characteristics, including absent inflammation and high fungal titers.
- Standard treatment responses are often poor, with high rates of relapse.
Purpose of the Study:
- To address key clinical questions regarding cryptococcal infections in HIV-positive individuals.
- To differentiate presentation and diagnosis between HIV-infected and non-HIV-infected patients.
- To provide guidance on optimal treatment and maintenance therapy.
Main Methods:
- Discussion of clinical presentations and diagnostic approaches.
- Evaluation of the sensitivity of cerebrospinal fluid (CSF) and serum cryptococcal antigen tests.
- Review of treatment options, including drug choices, dosages, and therapy duration.
Main Results:
- HIV-associated cryptococcal meningitis often presents with minimal inflammatory response.
- High fungal and antigen titers are characteristic in HIV-infected patients.
- Treatment with amphotericin B shows erratic responses, and relapse is common.
Conclusions:
- Diagnosis requires careful consideration of clinical presentation and sensitive antigen testing.
- Optimal treatment strategies are crucial to manage this opportunistic infection in HIV patients.
- Maintenance therapy may be necessary to prevent recurrent cryptococcal meningitis.